US Patent

US8143240 — 17Î±, 21-dihydroxypregnene esters as antiandrogenic agents

Method of Use · Assigned to Cosmo SpA · Expires 2027-01-12 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of 17Î±,21-dihydroxypregna-4,9-diene-3,20-dione and 17Î±,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters as antiandrogenic agents.

USPTO Abstract

17Î±,21-Dihydroxypregna-4,9-diene-3,20-dione and 17Î±,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof.

Drugs covered by this patent

Winlevi (CLASCOTERONE) · Sun Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2942`	—	Winlevi

Patent Metadata

Patent number: US8143240
Jurisdiction: US
Classification: Method of Use
Expires: 2027-01-12
Drug substance claim: No
Drug product claim: No
Assignee: Cosmo SpA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.